Yinggelai Pharmaceutical

Yinggelai Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on high-value targets in oncology and immunology, with a pipeline led by selective inhibitors such as CDK4/6 and TYK2. Yinggelai leverages its internal R&D capabilities to advance candidates from lead optimization through clinical proof-of-concept. Its mission is to provide effective and affordable treatment options for patients with unmet medical needs in the global market. The company is headquartered in the Suzhou Industrial Park, a major hub for Chinese biotech innovation.